Quantity of eligible patients: CDEC discussed the uncertainty in the amount of individuals with moderately intense to extreme hemophilia B in Canada eligible for etranacogene dezaparvovec. Scientific gurus consulted by CADTH indicated that some clients who're classified as owning delicate or reasonable disease can have a critical bleeding phenotype, which https://simonsybcc.onesmablog.com/the-best-side-of-hemgenix-76558029